Division of Cardiovascular Medicine, Core Technology Facility, University of Manchester, Manchester, UK.
Diabetes Care. 2011 Oct;34(10):2220-4. doi: 10.2337/dc11-1108. Epub 2011 Aug 18.
To assess, in the general diabetic population, 1) the prevalence of painful neuropathic symptoms; 2) the relationship between symptoms and clinical severity of neuropathy; and 3) the role of diabetes type, sex, and ethnicity in painful neuropathy.
Observational study of a large cohort of diabetic patients receiving community-based health care in northwest England (n = 15,692). Painful diabetic neuropathy (PDN) was assessed using neuropathy symptom score (NSS) and neuropathy disability score (NDS).
Prevalence of painful symptoms (NSS ≥5) and PDN (NSS ≥5 and NDS ≥3) was 34 and 21%, respectively. Painful symptoms occurred in 26% of patients without neuropathy (NDS ≤2) and 60% of patients with severe neuropathy (NDS >8). Adjusted risk of painful neuropathic symptoms in type 2 diabetes was double that of type 1 diabetes (odds ratio [OR] = 2.1 [95% CI 1.7-2.4], P < 0.001) and not affected by severity of neuropathy, insulin use, foot deformities, smoking, or alcohol. Women had 50% increased adjusted risk of painful symptoms compared with men (OR = 1.5 [1.4-1.6], P < 0.0001). Despite less neuropathy in South Asians (14%) than Europeans (22%) and African Caribbeans (21%) (P < 0.0001), painful symptoms were greater in South Asians (38 vs. 34 vs. 32%, P < 0.0001). South Asians without neuropathy maintained a 50% increased risk of painful neuropathy symptoms compared with other ethnic groups (P < 0.0001).
One-third of all community-based diabetic patients have painful neuropathy symptoms, regardless of their neuropathic deficit. PDN was more prevalent in patients with type 2 diabetes, women, and people of South Asian origin. This highlights a significant morbidity due to painful neuropathy and identifies key groups who warrant screening for PDN.
在一般糖尿病患者人群中,评估 1)疼痛性神经病变症状的患病率;2)症状与神经病变严重程度之间的关系;以及 3)糖尿病类型、性别和种族在疼痛性神经病变中的作用。
对英国西北部接受社区为基础的医疗保健的大量糖尿病患者队列(n=15692)进行观察性研究。使用神经病变症状评分(NSS)和神经病变残疾评分(NDS)评估疼痛性糖尿病性神经病变(PDN)。
疼痛症状(NSS≥5)和 PDN(NSS≥5 和 NDS≥3)的患病率分别为 34%和 21%。疼痛症状发生在无神经病变(NDS≤2)的患者中占 26%,在严重神经病变(NDS>8)的患者中占 60%。与 1 型糖尿病相比,2 型糖尿病患者发生疼痛性神经病变症状的风险增加了一倍(比值比[OR] = 2.1[95%CI 1.7-2.4],P<0.001),且不受神经病变严重程度、胰岛素使用、足部畸形、吸烟或饮酒的影响。与男性相比,女性发生疼痛症状的调整后风险增加了 50%(OR=1.5[1.4-1.6],P<0.0001)。尽管南亚人(14%)的神经病变比欧洲人(22%)和非洲加勒比人(21%)少(P<0.0001),但南亚人发生疼痛症状的比例更高(38%比 34%比 32%,P<0.0001)。与其他种族相比,无神经病变的南亚人发生疼痛性神经病变症状的风险仍增加 50%(P<0.0001)。
无论其神经病变缺失如何,三分之一的社区糖尿病患者都有疼痛性神经病变症状。2 型糖尿病、女性和南亚人患 PDN 的比例更高。这突出了疼痛性神经病变导致的显著发病率,并确定了需要筛查 PDN 的关键人群。